AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amylyx Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.33+0.99 (+3.76%)
Close on Oct 19, 2026
- Market cap
- $3.04B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -61.6% | |
| Return on assets | – | – | -55.0% | |
| Current ratio | – | – | 14.27 | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | – | 95M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Amylyx Pharmaceuticals generated $557.58M from operations and spent $4.42M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$557.58M
Used
$4.42M
Capital expenditure$4.42M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-345.4%
×Asset turnover0.25×
×Equity multiplier1.19×
=Return on equity, FY2024-100.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -345.4% | 0.25× | 1.19× | -100.9% |
| FY2023 | 12.9% | 0.84× | 1.17× | 12.7% |
| FY2022 | -892.4% | 0.09× | 2.62× | -209.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$144.74M
- Cash generatingOperating cash flow above zero-$123.34M
- Return on assets improvedROA up on the prior year-58.3% → -74.7%
- Earnings backed by cashOperating cash flow above net income-$123.34M vs -$144.74M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.67 → 14.27
- No dilutionShare count did not rise68M → 95M
- Gross margin improvedGross margin up on the prior year93.19% → –
- More efficientAsset turnover rose0.17 → 0.00